Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: A nested case-control study
| Autor: | Jakob Linseisen, Elio Riboli, Christina Bamia, Françoise Clavel-Chapelon, Kay-Tee Khaw, Piia Piret Eomois, Valentina Gallo, Ruth C. Travis, Nicholas J. Wareham, Antonia Trichopoulou, Amalia Mattiello, Pagona Lagiou, Neil Murphy, María Dolores Chirlaque, Elisabete Weiderpass, Heiner Boeing, Magritt Brustad, Aurelio Barricarte, Julie A. Schmidt, Susen Becker, Malin Sund, Guri Skeie, Carla H. van Gils, Anne Andersson, Rosario Tumino, Marina Kvaskoff, Fränzel J.B. Van Duijnhoven, Anja Olsen, Virginia Menéndez, Kim Overvad, Carlotta Sacerdote, Rudolf Kaaks, Anne Tjønneland, Laure Dossus, Sabina Rinaldi, Giovanna Masala, María José Sánchez, Genevieve Buckland, Tilman Kühn, Marije F. Bakker, Vittorio Krogh, Isabelle Romieu, Annekatrin Lukanova, H. Bas Bueno-de-Mesquita, Jenny Chang-Claude, Brian Buijsse |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
0303 health sciences Cancer Research medicine.medical_specialty Inverse Association business.industry medicine.medical_treatment Estrogen receptor Hormone replacement therapy (menopause) medicine.disease 3. Good health European Prospective Investigation into Cancer and Nutrition 03 medical and health sciences 0302 clinical medicine Breast cancer 030220 oncology & carcinogenesis Internal medicine Nested case-control study medicine Vitamin D and neurology business Prospective cohort study 030304 developmental biology |
| Zdroj: | International Journal of Cancer. 133:1689-1700 |
| ISSN: | 0020-7136 |
| Popis: | Experimental evidence suggests that vitamin D might play a role in the development of breast cancer. Although the results of case-control studies indicate that circulating 25-hydroxyvitamin D [25(OH)D] is inversely associated with the risk of breast cancer, the results of prospective studies are inconsistent. A case-control study embedded in the European Prospective Investigation into Cancer and Nutrition (EPIC) was carried out comprising 1,391 incident breast cancer cases and 1,391 controls. Multivariable conditional logistic regression models did not reveal a significant overall association between season-standardized 25(OH)D levels and the risk of breast cancer (ORQ4-Q1 [95% CI]: 1.07 [0.85-1.36], ptrend = 0.67). Moreover, 25(OH)D levels were not related to the risks of estrogen receptor positive tumors (ORQ4-Q1 [95% CI]: 0.97 [0.67-1.38], ptrend = 0.90) and estrogen receptor negative tumors (ORQ4-Q1 [95% CI]: 0.97 [0.66-1.42], ptrend = 0.98). In hormone replacement therapy (HRT) users, 25(OH)D was significantly inversely associated with incident breast cancer (ORlog2 [95% CI]: 0.62 [0.42-0.90], p = 0.01), whereas no significant association was found in HRT nonusers (ORlog2 [95% CI]: 1.14 [0.80-1.62], p = 0.48). Further, a nonsignificant inverse association was found in women with body mass indices (BMI) < 25 kg/m(2) (ORlog2 [95% CI]: 0.83 [0.67-1.03], p = 0.09), as opposed to a borderline significant positive association in women with BMI ≥ 25 kg/m(2) (ORlog2 [95% CI]: 1.30 [1.0-1.69], p = 0.05). Overall, prediagnostic levels of circulating 25(OH)D were not related to the risk of breast cancer in the EPIC study. This result is in line with findings in the majority of prospective studies and does not support a role of vitamin D in the development of breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text